Phyllis Gardner is Director at Revance Therapeutics, Inc. (RVNC). They have made 1 open-market trade across 1 company since 2018, most recently 2023-06-13.
CIK 0001238646
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RVNC | SELL | 2018-03-16 | 2018-03-16 | $31.51 | $336K | -3.2% | +3.9% | +0.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.